Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.345
-0.004 (-1.03%)
At close: Apr 28, 2026, 4:00 PM EDT
0.342
-0.003 (-0.84%)
After-hours: Apr 28, 2026, 7:22 PM EDT
Gossamer Bio Stock Forecast
GOSS's stock price has decreased by -64.01% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Gossamer Bio stock have an average target of 4.19, with a low estimate of 0.30 and a high estimate of 11. The average target predicts an increase of 1,114.84% from the current stock price of 0.34.
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2026.
Analyst Ratings
The average analyst rating for Gossamer Bio stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 3 | 3 | 4 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +1,349.70% | Mar 6, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $3 | Buy | Maintains | $12 → $3 | +769.82% | Mar 5, 2026 |
| Wedbush | Wedbush | Buy → Hold Downgrades $6 → $1 | Buy → Hold | Downgrades | $6 → $1 | +189.94% | Feb 24, 2026 |
| Barclays | Barclays | Buy → Sell Downgrades $9 → $0.3 | Buy → Sell | Downgrades | $9 → $0.3 | -13.02% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
20.54M
from 48.47M
Decreased by -57.63%
Revenue Next Year
61.94M
from 20.54M
Increased by 201.64%
EPS This Year
-0.49
from -0.75
EPS Next Year
-0.19
from -0.49
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 39.6M | 117.9M | ||||||
| Avg | 20.5M | 61.9M | ||||||
| Low | n/a | 19.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -18.2% | 473.9% | ||||||
| Avg | -57.6% | 201.6% | ||||||
| Low | - | -5.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.21 | -0.02 | ||||||
| Avg | -0.49 | -0.19 | ||||||
| Low | -0.77 | -0.42 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.